STAT

STAT Plus: Pharmalittle: BioNTech expects to seek approval for vaccine by year-end; why the FDA chose a 50% threshold for Covid-19 vaccines

Peter Marks, a top FDA official, shed light on the reasoning behind the agency's choice of a 50% efficacy threshold for a Covid-19 vaccine.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min lettiMedical
STAT+: Pharmalittle: Novavax Faces Raw-materials Shortages For Covid-19 Shot; India Curbs Vaccine Exports
Novavax is delaying signing a contract to supply its Covid-19 vaccine to the European Union because the company is struggling to source raw materials.
STAT1 min lettiMedical
STAT+: Pharmalittle: J&J Seeks Emergency Use For Its Coronavirus Vaccine; Merck Says Parasite Drug Does Not Work On Covid-19
Johnson & Johnson has applied to the FDA for an emergency use authorization for its one-dose Covid-19 vaccine, setting in motion a process all but sure to see a third…
STAT1 min lettiMedical
STAT+: Pharmalittle: Single Pfizer Shot Is 85% Effective In Preventing Symptomatic Covid-19; Biden To Commit $4 Billion To COVAX
An Israeli study found that a single shot of the Covid-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) is 85% effective in preventing symptomatic disease.